Julie Hallet: Cabozantinib vs placebo for NETs
Julie Hallet, Associate Scientist at Sunnybrook Health Sciences Centre and Assistant Professor of General Surgery at Temerty Faculty of Medicine, University of Toronto, shared a post on X, about recent paper published in The New England Journal of Medicine:
Phase 3 Trial of Cabozantinib to Treat Advanced Neuroendocrine Tumors.
Authors: Jennifer A. Chan, Susan Geyer, Tyler Zemla, Michael V. Knopp, Spencer Behr, Sydney Pulsipher, Fang-Shu Ou, Amylou C. Dueck, Jared Acoba, Ardaman Shergill, Edward M. Wolin, Thorvardur R. Halfdanarson, Bhavana Konda, Nikolaos A. Trikalinos, Bernard Tawfik, Nitya Raj, Shagufta Shaheen, Namrata Vijayvergia, Arvind Dasari, Jonathan R. Strosberg, Elise C. Kohn, Matthew H. Kulke, Eileen M. O’Reilly, Jeffrey A. Meyerhardt.
”More options for Neuroendocrine Tumors (NETs).
Hot off the press CABINET in The New England Journal of Medicine at ESMO24.
Locally advanced or metastatic Neuroendocrine Tumors (NETs) heavily (closed early for efficacy). Cabozantinib versus placebo. Progression-free survival (PFS) for extra-pancreatic NETs (hazard ratio [HR] 0.38) and pancreatic NETs (PNET) (HR 0.23). Response rate is low: overall response rate (ORR) 5% and 19%.
Congratulations Jennifer A. Chan and team!”
Source: Julie Hallet/X
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023